

## What is the purpose of launching *World Journal of Respirology*?

Rafael Rosell

Rafael Rosell, Medical Oncology Service, Catalan Institute of Oncology, 08916 Badalona (Barcelona), Spain

Author contributions: Rosell R solely contributed to this paper. Correspondence to: **Rafael Rosell, MD, Head**, Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 Badalona (Barcelona), Spain. [rosell@iconcologia.net](mailto:rosell@iconcologia.net)

Telephone: +34-93-4978925 Fax: +34-93-4978950

Received: December 3, 2011 Revised: December 13, 2011

Accepted: December 22, 2011

Published online: December 30, 2011

### Abstract

Congratulations to the publisher, members of the editorial board of the journal, and all the authors and readers for launching the *World Journal of Respirology* (*WJR*). The *WJR* is a peer-reviewed journal that will report novel theories, methods and techniques for the prevention, diagnosis, treatment, rehabilitation and nursing of patients with respiratory disease. Some of the topics that will be covered in the journal include diagnostic imaging, respiratory physiology, respiratory endoscopy, respiratory system tumors, chronic obstructive pulmonary disease, bronchial asthma, respiratory infections, critical respiratory illness, sleep-related respiratory disorders, interstitial lung disease, pulmonary vascular diseases, pulmonary embolism, traditional medicine, integrated Chinese and Western medicine, evidence-based medicine, epidemiology and nursing. Importantly, the *WJR* is an online, open-access journal, which will enable it to reach both experts and the general public without the need for registration or payment. If you want to share your work and findings, you will find the *WJR* an excellent journal for your publications!

© 2011 Baishideng. All rights reserved.

**Key words:** Open-access; Peer-reviewed; Respiratory disease; Genomic medicine



**Figure 1** Editor-in-Chief of the *World Journal of Respirology*. Rafael Rosell, MD, Head, Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 Badalona (Barcelona), Spain.

**Peer reviewers:** Mike Niederman, MD, Chairman, Professor of Medicine, Department of Medicine, Winthrop University Hospital, 222 Station Plaza N., Suite 509, Mineola, NY 11501, United States; Nawwar Al-Attar, MB, ChB, FRCS, FETCS, PhD, Associate Professor, Department of Cardiac Surgery, Hospital Bichat, 46 rue Henri Huchard, 75018 Paris, France

Rosell R. What is the purpose of launching *World Journal of Respirology*? *World J Respirol* 2011; 1(1): 1-2 Available from: URL: <http://www.wjgnet.com/2218-6255/full/v1/i1/1.htm> DOI: <http://dx.doi.org/10.5320/wjr.v1.i1.1>

### INTRODUCTION

I am Rafael Rosell, MD, Head, Medical Oncology Service Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Figure 1). As Editor-in-Chief of the *World Journal of Respirology* (*World J Respirol*, *WJR*, online ISSN 2218-6255, DOI: 10.5320), it is a great pleasure for me to introduce this new journal as a forum where investigators, physicians, nurses, radiologists and paramedical personnel can exchange ideas and findings in the field of respiratory disease. The *WJR* Editorial Board has now been established and consists of 84 distinguished experts from 30 countries. I am very pleased to announce that the first

issue of the *WJR*, was initiated on December 9, 2010, and was officially published on December 30, 2011. I would like to extend my congratulations to the publisher, the members of the editorial board, and all the authors and readers of the journal for this important launch.

## SCOPE

The *WJR* is a peer-reviewed journal that will report novel theories, methods and techniques for the prevention, diagnosis, treatment, rehabilitation and nursing of patients with respiratory disease. Some of the topics that will be covered in the journal include diagnostic imaging, respiratory physiology, respiratory endoscopy, respiratory system tumors, chronic obstructive pulmonary disease, bronchial asthma, respiratory infections, critical respiratory illness, sleep-related respiratory disorders, interstitial lung disease, pulmonary vascular diseases, pulmonary embolism, traditional medicine, integrated Chinese and Western medicine, evidence-based medicine, epidemiology and nursing. The journal will publish both original articles and reviews of applied and basic research in several fields, including immunology, physiopathology, cell biology, pharmacology, medical genetics, and the pharmacology of Chinese herbs.

## OPEN-ACCESS FORMAT

Importantly, the *WJR* is an online, open-access journal, which will enable it to reach both experts and the general public without the need for registration or payment. The open-access format also reduces the delay in publication often associated with traditional journals and maximizes the benefit to readers and authors. Readers will have unlimited access to free, high-quality, peer-reviewed articles reporting viewpoints, concepts, theories, and results, and in this way, they will be able to validate the scientific and practical values of their own research. At the same time, authors will have the widest possible audience for their articles, thus optimizing potential communication between authors and their peers.

## NEW PERSPECTIVE

Genomic medicine is becoming part of patient care. In respiratory diseases, this will be one element that will be integrated in *WJR* for rapid conceptualization. Recent examples have illustrated that BIBF 1120, a tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFRs), has led to substantial improvement in idiopathic pulmonary fibrosis<sup>[1]</sup> and in a number of cancers<sup>[2]</sup>. Frequent focal FGFR1 amplification was identified in

squamous cell lung cancer<sup>[3]</sup>, and FGFR1 dependency could become therapeutically relevant.

## CONTENTS OF PEER REVIEW

The *WJR* is a bimonthly peer-reviewed, online, open-access, journal supported by an editorial board consisting of 84 experts in respirology from 30 countries. In order to guarantee the quality of articles published in the journal, *WJR* usually invites three experts to comment on the submitted papers. The contents of peer review include: (1) whether the contents of the manuscript are of great importance and novelty; (2) whether the experiment is complete and described clearly; (3) whether the discussion and conclusion are justified; (4) whether the citations of references are necessary and reasonable; and (5) whether the presentation and use of tables and figures are correct and complete.

## COLUMNS

*WJR* articles will include Editorials, Frontier Articles, Topic Highlights, Observations, Guidelines for Clinical Practice, Reviews, Original Articles, Brief Articles, Case Reports, Letters to the Editor, and Book Reviews. I invite all investigators, physicians, nurses, radiologists and paramedical personnel to share their ideas and findings in the forum provided by the *WJR*.

## REFERENCES

- 1 **Ley B**, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2011; **183**: 431-440
- 2 **Richeldi L**, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglic M, du Bois RM. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *N Engl J Med* 2011; **365**: 1079-1087
- 3 **Weiss J**, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heuckamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sängler J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S, Thomas RK. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci Transl Med* 2010; **2**: 62ra93

S- Editor Wu X L- Editor Wang TQ E- Editor Li JY